Abstract Library

#1020 Peptide Receptor Radionuclide Therapy for Progressive and Metastatic Neuroendocrine Tumors: Analysis of Efficacy in 1000 Patients from a Single Center

Introduction: Peptide receptor radionuclide therapy (PRRT) is beneficial in well-differentiated neuroendocrine tumors (NETs).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Kulkarni H

Authors: Baum R, Kulkarni H, Zachert C, Kaemmerer D, Petrovitch A,

Keywords: PRRT,

#238 Peptide Receptor Radionuclide Therapy (PRRNT) in Patients with Metastasized Neuroendocrine Tumor Having Single or Non-functional Kidney - Is it Safe?

Introduction: Nephrotoxicity is one of the primary concerns in PRRNT of metastasized neuroendocrine tumors (NET).

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Prasad V, Hoersch D, Zachert C, Baum R,

Keywords: single kidney, non-functional kidney, peptide receptor radionuclide therapy, NET,

#236 Very Long-term Follow-up (> 5 years) of Renal Function of Neuroendocrine Tumor Patients Treated with Five or More Cycles of Peptide Receptor Radionuclide Therapy (PRRNT)

Introduction: Nephrotoxicity is one of the primary concerns in neuroendocrine tumor (NET) patients (pts.) treated with peptide receptor radionuclide therapy (PRRNT).

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Prasad V, Hoersch D, Zachert C, Hommann M, Baum R,

Keywords: Peptide Receptor Radionuclide Therapy, NET, nephrotoxicity, long-term follow-up,

#161 Low Dose Multiple Cycle (LD/MT) Peptide Receptor Radionuclide Therapy: a new concept for the treatment of well-differentiated metastatic neuroendocrine tumors

Introduction: It has been shown experimentally that low dose radiation can effectively kill slow growing cancer cells. Also, external beam radiation therapy applies a fractionated delivery of radiation dose to reduce toxicity with equal or even better therapeutic efficacy.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Prasad V, Roether M, Zachert C, Baum R,

Keywords: Peptide Receptor Radionuclide Therapy (PRRT), low dose multiple cycle, well-differentiated neuroendocrine tumors,

#156 Toxicity, response and survival analyses of Peptide Receptor Radionuclide Therapy (PRRT) in treatment refractory metastatic thyroid cancer using Yttrium-90 and Lutetium-177 Labeled somatostatin analogs

Introduction: Medullary thyroid carcinoma (MTC) represents about 3-16% of thyroid cancer. After first line treatment, therapeutic options for locally recurrent or metastasizing tumors include repeated surgery, whenever possible. Doxorubicin containing chemotherapy regimens in iodine-nonavid differentiated thyroid cancer have poor efficacy.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Prasad V, Budiawan H, Ali S, Hoersch D, Zachert C,

Keywords: Peptide Receptor Radionuclide Therapy (PRRT), thyroid cancer, survival, toxicity, response,